Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 19, 2016Expert Review of Hematology

Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

JDJenny DahlKMKayleigh MarxThe University of Texas MD Anderson Cancer Center
Elias Jabbour
Elias JabbourLiechtenstein Institute

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Dahl et al. (2016) studied this question.

synapsesocial.com/papers/6aaf3509a7e31fa2e934fb5dhttps://doi.org/10.1586/17474086.2016.1143771
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia2013 · 300 citations
  2. 2Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation2012 · 479 citations
  3. 3Current medical diagnosis & treatment2009 · 308 citations